Regarding the development of sublingual tablets for the treatment of diseases of the oral mucosa

Authors

DOI:

https://doi.org/10.14739/2409-2932.2026.2.362533

Keywords:

thiotriazolin, decamethoxin, tablets, direct compression, State Pharmacopoeia of Ukraine, pharmaco-technological indicators

Abstract

The need to create new sublingual tablets for the treatment of diseases of the oral mucosa is due to the insufficient number of domestic drugs on the pharmaceutical market. Therefore, the development of tablets based on thiotriazolin and decamethoxin, as a potentially new drug, for the treatment of diseases and the sanitation of the oral cavity in pathological conditions such as gingivitis, stomatitis, etc. is an urgent task for pharmacy and medicine.

The aim of the work is to develop a rational tablet composition, justify the choice of excipients in its composition and analyze the dosage form according to pharmaco-technological indicators in accordance with the requirements of the State Pharmacopoeia of Ukraine.

Materials and methods. Active substances – thiotriazolin and decamethoxin; excipients (based on microcrystalline cellulose, granulated sugars, glidants, lubricants and baking powders). During the study powder mixtures were tested for bulk density after compaction, fluidity and angle of natural slope. Further, the compressed series of tablets were tested for strength, disintegration and abrasion in accordance with the requirements of the State Pharmacopoeia of Ukraine.

Results. As a result of the research, we found that the manufactured series of tablets when assessing their pharmacokinetic properties do not have stable established indicators that are regulated by the State Pharmacopoeia of Ukraine. Therefore, an analysis of foreign and domestic literature sources was conducted regarding tablets containing decamethoxin as the active ingredient. Also, in the process of experimental research, a new composition of tablets based on thiotriazolin with decamethoxin by direct compression has already been developed and a comparative analysis of their pharmacokinetic properties has been conducted.

Conclusions. During the work, the choice of excipients was justified, the possibility of obtaining tablets by direct compression was experimentally confirmed, and their optimal composition was developed, which meets the basic requirements of the State Pharmacopoeia of Ukraine.

Author Biographies

L. I. Kucherenko, Zaporizhzhia State Medical and Pharmaceutical University

PhD, DSc, Professor, Head of the Department of Pharmaceutical and Bioorganic Chemistry

O. O. Chonka, Zaporizhzhia State Medical and Pharmaceutical University

Postgraduate Student at the Department of Pharmaceutical and Bioorganic Chemistry

References

  1. Kolenko Y, Synko A. [Impact of chronic oral mucosal disease onon the patients’ quality of life]. Suchasna stomatolohiia. 2023;(4):4-9. Ukrainian. doi: https://doi.org/10.33295/1992-576X-2023-4-4
  2. Plewa MC, Chatterjee K. Recurrent Aphthous Stomatitis. [Updated 2023 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431059/
  3. Faustova MO, Chumak YV, Loban’ GA, Ananieva MM, Havryliev VM. Decamethoxin and chlorhexidine bigluconate effect on the adhesive and biofilm-forming properties of Streptococcus mitis. Front Oral Health. 2023;4:1268676. doi: https://doi.org/10.3389/froh.2023.1268676
    | |
  4. Muntian OV, Muntian VL. Analiz zakhvoriuvan slyzovoi obolonky porozhnyny rota u vnutrishno peremishchenykh osib. In: Poltavski dni hromadskoho zdorovia. Proceedings of the 7th International scientific and practical conference [Internet]; 2024 May 31; Poltava, Ukraine; 2024 [cited 2026 May 2]. p. 259-61. Ukrainian. Available from: https://repository.pdmu.edu.ua/handle/123456789/24799
  5. European Medicines Agency. ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances – Step 5 (CPMP/ICH/367/96). European Medicines Agency: European Union; 2020. 32 р.
  6. Hroshovyi TA, Demchuk MB, Beley NM, Nayda YV, Pavliuk BV. [Experimental design in research at the creation of tablet medicines]. Pharmaceutical Review. 2020;(2):101-10. Ukrainian. doi: https://doi.org/10.11603/2312-0967.2020.2.11204
  7. Babina YM, Nazarchuk OA, Dmytriiev DV, Rymsha OV, Behma MA. [Research of sensitivity of clinical strains of S. Aureus to decamethoxin and local anesthetics]. Art of medicine. 2020;3:17-22. Ukrainian. doi: https://doi.org/10.21802/artm.2020.3.15.17 10.21802/artm.2020.3.15.17
  8. Faustova MO, Chumak YV, Lokes KP, Lobanʼ GA, Steblovskyi DV, Voloshyna LІ, et al. Decamethoxine reduces the adhesive properties of streptococci isolated from patients with dry socket. Kharkiv Dental Journal. 2025;2(4):594-605. doi: https://doi.org/10.26565/3083-5607-2025-6-06
    |
  9. Kucherenko LI, Bielenichev IF, Chonka OО, Moriak ZB, Portna OO. Study of the antimicrobial and fungicidal activity of thiotriazoline and decamethoxinum as a potentially new model mixture for use of the oral mucosa. Current issues in pharmacy and medicine: science and practice. 2020;13(3):349-53. doi: https://doi.org/10.14739/2409-2932.2020.3.216197
  10. Kucherenko LI, Chonka OO, Portna OO. Development of methods for standardization of the active substance, namely the model mixture based on decamethoxine and thiotriazoline. Zaporozhye Medical Journal. 2021;23(5):703-7. doi: https://doi.org/10.14739/2310-1210.2021.5.225459
  11. Kucherenko L, Chonka O, Shishkina S. Theoretical study of the possibility of decamethoxin complexes with thiotriazolinе to be formed. Sciencerise: Pharmaceutical Science. 2021(4):37-42. doi: https://doi.org/10.15587/2519-4852.2021.239279
    |
  12. Benzian H, Beltràn-Aguilar E. The return of oral health to global health is significant for public health everywhere. J Public Health Dent. 2021;81(2):87-9. doi: https://doi.org/10.1111/jphd.12457
    | |
  13. Skrypnykov PM, Skrypnikova TP, Lupatsa NA, Raskolupa NV, Ostrovska GY, Titarenko VI, et al. [Oral health status of internally displaced persons]. Ukrainian Dental Almanac. 2023;(1):12-6. Ukrainian. doi: https://doi.org/10.31718/2409-0255.1.2023.02
  14. Vo T, Chu PM, Tuan VP, Te JS, Lee IT. The Promising Role of Antioxidant Phytochemicals in the Prevention and Treatment of Periodontal Disease via the Inhibition of Oxidative Stress Pathways: Updated Insights. Antioxidants (Basel). 2020;9(12):1211. doi: https://doi.org/10.3390/antiox9121211
    | |
  15. Bielenichev IF, Vіzіr VA, Mamchur VY, Kuriata OV. [Place of tiotriazoline in the gallery of modern metabolitotropic medicines]. Zaporozhye Medical Journal. 2019;21(1):118-28. doi: https://doi.org/10.14739/2310-1210.2019.1.155856

Downloads

Additional Files

Published

2026-06-26

How to Cite

1.
Kucherenko LI, Chonka OO. Regarding the development of sublingual tablets for the treatment of diseases of the oral mucosa. Current issues in pharmacy and medicine: science and practice [Internet]. 2026Jun.26 [cited 2026Jun.26];19(2):174-8. Available from: https://pharmed.zsmu.edu.ua/article/view/362533

Issue

Vol. 19 No. 2 (2026)

Section

Original research

License

Copyright (c) 2026 L. I. Kucherenko, O. O. Chonka

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
 Лицензия Creative Commons